Radius Health to Present at 10th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health announced it will present a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on February 25, 2021. The presentation will be accessible via a live webcast on the Company's website, with a replay available for 90 days afterwards.

Radius is focused on developing endocrine therapeutics, with its lead product TYMLOS® approved for treating high-risk postmenopausal women with osteoporosis. The company has additional investigational drugs targeting osteoporosis and hormone-receptor positive breast cancer.

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it will provide a corporate update at the 10^th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on Thursday, February 25, 2021.

A live webcast of the presentation will be available by visiting the Investors section of the Company’s website at https://ir.radiuspharm.com/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.

Investor & Media Relations Contact:
Peter Schwartzman
Email: investor-relations@radiuspharm.com
Phone: (617) 583-2017

FAQ

What is Radius Health's presentation date at the SVB Leerink Global Healthcare Conference?

Radius Health will present on February 25, 2021.

What time will Radius Health present at the conference?

Radius Health's presentation is scheduled for 10:40 a.m. ET.

How can I access the Radius Health presentation?

The presentation will be available via a live webcast on Radius Health's website.

What is TYMLOS® and who is it for?

TYMLOS® is an injection approved for postmenopausal women with osteoporosis at high risk for fracture.

What investigational drugs are in Radius Health's pipeline?

Radius has investigational drugs for osteoporosis and hormone-receptor positive breast cancer among others.